Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
This study has been completed.
Children's Oncology Group
Information provided by:
National Cancer Institute (NCI)
First received: April 7, 2003
Last updated: October 23, 2012
Last verified: November 2010
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||October 2009 (Final data collection date for primary outcome measure)|
Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2012 Sep 3. doi: 10.1038/leu.2012.255. [Epub ahead of print]
Goldman S, Lynch J, Harrison L, et al.: Preliminary results of the addition of rasburicase to the reduction cycle and rituximab to the induction and consolidation cycles of FAB group C chemotherapy in children and adolescents with advanced stage (bone marrow ±CNS) mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report . [Abstract] Blood 114 (22): A-104, 2009.
Cairo MS, Lynch J, Harrison L, et al.: Safety, efficacy and rituximab levels following chemoimmunotherapy (rituximab + FAB chemotherapy) in children and adolescents with mature B-cell Non-Hodgkin lymphoma (B-NHL): a Children's Oncology Group report. [Abstract] Blood 112 (11): A-838, 2008.